Welcome!

News Feed Item

Response Biomedical Corp. Announces Second Quarter 2014 Financial Results

VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 08/11/14 -- Response Biomedical Corp. ("Response" or "the Company") (TSX:RBM)(OTCBB:RPBIF) today reported financial results for the second quarter and six months ended June 30, 2014 including a 12% increase in sales and improving gross margin.

Response's Chief Executive Officer, Jeff Purvin, commented on Response's Q2 2014 performance saying, "I am happy to report that our new China distributors are continuing to place new orders this quarter. Total sales in China were approximately $350 thousand more in this quarter than last quarter, indicating that these distributors are starting to work through their initial stocking inventories and are developing new demand in the marketplace."

Mr. Purvin added, "Sales in the US were relatively unchanged from the previous year with the exception of Biodefense and West Nile Virus testing sales which increased by 30%, primarily due to the successful sales efforts of our distributors and the timing of orders. US cardiac sales have been slower than we expected and we are in the process of refocusing our resources on the specific hospital groups and other opportunities that will benefit the most from our products. We will be reallocating some of our current US spending over to China, where it will likely have a more immediate impact on our sales growth, this year and next. Sales in the rest of the world, excluding China and the US, increased 22% versus last year to $674 thousand in the quarter as we continue to strengthen our overseas distribution networks. This growth was hampered by lower quarter over quarter sales to our Russian distributor due to factors resulting from the recent unrest in that country. Russia is our second biggest market after China.

"Importantly, we were able to improve our gross margin percentage during the quarter to 44.6%. The efficiencies we've achieved in manufacturing and purchasing over the past year, along with positive exchange fluctuations, have contributed to the improvement in margin. We anticipate that these efficiencies will continue to benefit the company in the future as our unit sales volumes increase. All of the changes we are making now will require time to take full effect. However, because of the quality and quantity of the changes we've made, I feel confident that this plan will allow Response Biomedical to accelerate revenue growth and speed our progress toward profitability," concluded Mr. Purvin.

Financial results for the three months ended June 30, 2014


--  Product sales increased 12% to $3.08 million for the quarter ended June
    30, 2014 compared to $2.75 million for the same quarter in the previous
    year ended June 30, 2013: 
    
    --  Cardiovascular sales increased 9%, or $0.22 million, primarily due
        to increased sales in China as a result of the transition to new
        distribution partners; and 
        
    --  Infectious Disease, West Nile Virus and Biodefense sales increased
        30%, or $0.11 million compared to 2013, primarily due to the
        successful sales efforts of our distributors and the timing of
        orders. 
        
--  Gross margin increased to 44.6% for the quarter ended June 30, 2014,
    compared to a gross margin of 41.6% in the same quarter of 2013. This
    increase is primarily due to the numerous manufacturing efficiencies
    implemented along with reduced component material costs through price
    and volume negotiations and by purchasing from more economical
    suppliers. In addition, there was a decrease in inventory provisions
    along with a positive impact on our gross margin by an appreciated U.S.
    dollar. 
    
--  Operating expenses decreased by 12% to $1.88 million for the quarter
    ended June 30, 2014 compared to $2.13 million in the same quarter of
    2013. This decrease is primarily due to decreases in legal and stock
    based compensation expenses offset by increased spending in research and
    development for clinical and regulatory work in 2014.  
    
--  As a result of the changes described above, Adjusted EBITDA for the
    quarter ended June 30, 2014 improved to negative $0.23 million compared
    to negative $0.56 million in the same quarter of 2013. Adjusted EBITDA
    excludes, for the applicable periods, interest expense, interest income,
    income tax, depreciation and amortization, stock-based compensation
    expense, and the non-cash unrealized gain or loss on the revaluation of
    the warrant liability. We believe that this non-GAAP measure may be
    useful to investors to analyze the results of our business as we use
    this non-GAAP measure internally to evaluate our financial results. A
    reconciliation between net income (loss) and comprehensive income (loss)
    and Adjusted EBITDA is included below. 
    
--  GAAP Net income for the quarter ended June 30, 2014 totaled $0.29
    million, or $0.04 per basic and diluted share, compared to $3.34 million
    GAAP Net income, or $0.51 per basic share and a loss of $0.14 per
    diluted share, in the comparative 2013 period. The decrease in GAAP Net
    income was primarily due to a $3.43 million decrease in the unrealized
    gain on revaluation of the warrant liability offset by the increase in
    product sales and decrease in operating expenses mentioned above. 
    
--  Adjusted Net loss decreased by $0.38 million to $0.75 million from $1.13
    million in the comparable quarter in 2013. We also believe that this
    non-GAAP measure, along with Adjusted EBITDA, may be useful to investors
    to analyze the results of our business because it excludes the often
    volatile, non-cash unrealized change in the valuation of the Company's
    warrant liability. A reconciliation between Net income (loss) and
    comprehensive income (loss) and Adjusted Net loss is included below.  

Financial results for the six months ended June 30, 2014


--  Product sales decreased 11% to $5.64 million for the six month period
    ended June 30, 2014 compared to $6.31 million for the comparative period
    ended June 30, 2013: 
    
    --  Cardiovascular sales decreased 4%, or $0.19 million, primarily due
        to reduced sales in China in the first quarter as a result of the
        transition to new distribution partners which began in the fourth
        quarter of 2013; and 
        
    --  Infectious Disease, West Nile Virus and Biodefense sales have
        decreased 45%, or $0.48 million compared to 2013, primarily due to
        the seasonal increase in demand for Influenza sales in the first
        quarter of 2013 and the timing of orders by distributors. 
        
--  Gross margin increased to 44.2% for the six months ended June 30, 2014,
    compared to a gross margin of 43.4% in the same period of 2013. This
    increase is primarily due to numerous manufacturing efficiencies along
    with reduced component material costs by improved purchasing offsetting
    the impact of a decrease in our non-cardiovascular sales, which are sold
    at higher margins, described above. 
    
--  Operating expenses increased by 4% to $4.15 million for the six months
    ended June 30, 2014 compared to $3.99 million in the same period in
    2013. The increase is primarily due to increased spending in research
    and development for clinical and regulatory work in 2014 and an increase
    in sales and marketing expenses primarily related to expanded staffing
    offset by decreased general and administrative costs.  
    
--  As a result of the changes described above, Adjusted EBITDA for the six
    months ended June 30, 2014 was negative $1.03 million compared to
    negative $0.41 million in the same period of 2013 as a result of the
    decrease in product sales and increase in operating expenses described
    above. 
    
--  GAAP Net loss for the six months ended June 30, 2014 totaled $1.03
    million, or $0.16 per basic and diluted share, compared to a $6.62
    million GAAP Net loss, or $1.01 per basic and diluted share, in the
    comparative 2013 period. The decrease in the loss was primarily due to a
    $5.98 million decrease in the unrealized loss on revaluation of the
    warrant liability offset by the decrease in product sales and increase
    in operating expenses mentioned above. 
    
--  Adjusted Net loss for the six months ended June 30, 2014 increased by
    $0.59 million to $2.11 million from $1.52 million in the comparable
    period in 2013. 
    
--  Cash and cash equivalents as of June 30, 2014 were $2.61 million
    compared to $2.96 million as of December 31, 2013. During the six month
    period, the Company received US $1.5 million of the total US $2.5
    million term loan from Silicon Valley Bank that it had secured during
    the first quarter of 2014.  

For a further discussion of the Company's financial results for the second quarter ended June 30, 2014, please refer to the Company's consolidated financial statements and related Management Discussion and Analysis, which can be found at www.responsebio.com, SEDAR (Canada) www.sedar.com or EDGAR (U.S.) www.sec.gov/edgar/searchedgar/webusers.htm. Information at these sites is typically available within 24 hours of the distribution of the news release.

Non-GAAP Financial Measures

Management has presented its operating results in accordance with United States Generally Accepted Accounting Principles (GAAP) and on an "adjusted" (or non-GAAP) basis for the three and six months ended June 30, 2014 and 2013. We believe that the presentation of non-GAAP financial measures provides useful supplementary information to and facilitates additional analysis by investors. These non-GAAP financial measures are in addition to, not a substitute for, or superior to, measures of financial performance prepared in conformity with GAAP. Further, our reconciliation of GAAP Net income (loss) and comprehensive income (loss) to Adjusted EBITDA and Adjusted Net loss are included in the tables below to facilitate a reader's understanding of the impact of these adjustments to our GAAP financial results and are not intended to place any undue prominence on our Adjusted EBITDA and/or our Adjusted Net loss.

About Response Biomedical Corp.

Response develops, manufactures and markets rapid on-site diagnostic tests for use with its RAMP® Platform for clinical, biodefense and environmental applications. RAMP® represents a unique paradigm in diagnostics that provides reliable, quality results in minutes. The RAMP® Platform consists of a reader and single-use disposable test cartridges and has the potential to be adapted to any other medical and non-medical immunoassay based test currently performed in laboratories. Response clinical tests are commercially available for the aid in early detection of heart attack, congestive heart failure, influenza A and B and RSV. In the non-clinical market, RAMP® tests are currently available for the environmental detection of West Nile Virus and for Biodefense applications including the rapid on-site detection of anthrax, smallpox, ricin and botulinum toxin.

Response is a publicly traded company listed on the TSX under the trading symbol "RBM" and quoted on the OTC Bulletin Board under the symbol "RPBIF". For further information, please visit the Company's website at www.responsebio.com.

Forward-Looking Statements

This press release may contain forward-looking statements. These statements relate to future events and are subject to risks, uncertainties and assumptions about Response Biomedical Corp. Examples of forward-looking statements in this press release include statements regarding our belief that our new distributors in China are starting to work through their initial stocking inventories and are developing new demand in the marketplace, our belief that reallocating some of our current US spending over to China will likely have a more immediate impact on our sales growth, this year and next, our belief that the efficiencies we have achieved in manufacturing and purchasing over the past year will benefit the Company in the future as our unit sales volumes increase, our expectation that all of the changes we are making now will require time to take full effect and our belief that the quality and quantity of the changes we've made will allow us to accelerate revenue growth and speed our progress toward profitability. These statements are only predictions based on our current expectations and projections about future events. Although we believe the expectations reflected in such forward-looking statements, and the assumptions upon which such forward-looking statements are made, are reasonable, there can be no assurance that such expectations will prove to be correct and if such expectations are not met, our business may suffer.

Readers should not place undue reliance on these statements. Actual events or results may differ materially. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Many factors may cause the Company's actual results to differ materially from any forward-looking statement, including the factors detailed in our filings with the Securities and Exchange Commission and Canadian securities regulatory authorities, including but not limited to our annual report on Form 10-K, our quarterly reports on Form 10-Q, our Current Reports on Form 8-K, our Annual Information Form and other filings with the Securities and Exchange Commission and Canadian securities regulatory authorities.

The forward-looking statements contained in this news release are current as of the date hereof and are qualified in their entirety by this cautionary statement. Except as expressly required by applicable securities laws, we do not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

Selected Financial Data (in thousands of Canadian dollars except per share data):


                               Three Months Ended       Six Months Ended    
                                    June 30                 June 30         
                                   2014        2013        2014        2013 
----------------------------------------------------------------------------
Product sales                 $   3,077   $   2,748   $   5,636   $   6,309 
Cost of sales                     1,705       1,606       3,145       3,571 
                            ------------------------------------------------
Gross profit on product                                                     
 sales                        $   1,372   $   1,142   $   2,491   $   2,738 
Gross margin on product                                                     
 sales                             44.6%       41.6%       44.2%       43.4%
Operating expenses                1,882       2,130       4,150       3,993 
Other expenses (excluding                                                   
 unrealized loss (gain) on                                                  
 revaluation of warrant                                                     
 liability)                         241         139         454         261 
                            ------------------------------------------------
Adjusted net loss             $    (751)  $  (1,127)  $  (2,113)  $  (1,516)
                            ------------------------------------------------
Unrealized loss (gain) on                                                   
 revaluation of warrant                                                     
 liability                       (1,039)     (4,470)       (878)      5,105 
                            ------------------------------------------------
Net income (loss) and                                                       
 comprehensive income (loss)                                                
 for the period               $     288   $   3,343   $  (1,235)  $  (6,621)
                            ------------------------------------------------
                            ------------------------------------------------
Income (loss) per share -                                                   
 basic                        $    0.04   $    0.51   $   (0.16)  $   (1.01)
Income (loss) per share -                                                   
 diluted                      $    0.04   $   (0.14)  $   (0.16)  $   (1.01)

Reconciliation of GAAP Net Income (Loss) to Adjusted EBITDA (in thousands of Canadian dollars):


                               Three Months Ended       Six Months Ended    
                                    June 30                 June 30         
                                   2014        2013        2014        2013 
----------------------------------------------------------------------------
Adjusted EBITDA               $    (227)  $    (563)  $  (1,029)  $    (412)
Interest expense and                                                        
 amortization of deferred                                                   
 financing costs and debt                                                   
 discount                           226         175         423         351 
Interest income                      (4)         (4)         (9)         (7)
Income tax expense                   15          14          32          14 
Depreciation and                                                            
 amortization                       205         198         405         430 
Stock-based compensation             82         181         233         316 
Unrealized loss (gain) on                                                   
 revaluation of warrant                                                     
 liability                       (1,039)     (4,470)       (878)      5,105 
                            ------------------------------------------------
Net income (loss) and                                                       
 comprehensive income (loss)                                                
 for the period               $     288   $   3,343   $  (1,235)  $  (6,621)
                            ------------------------------------------------
                            ------------------------------------------------

Reconciliation of Adjusted Net Loss to GAAP Net Income (Loss) (in thousands of Canadian dollars):


                               Three Months Ended       Six Months Ended    
                                    June 30                 June 30         
                                   2014        2013        2014        2013 
----------------------------------------------------------------------------
Adjusted net loss             $    (751)  $  (1,127)  $  (2,113)  $  (1,516)
Unrealized loss (gain) on                                                   
 revaluation of warrant                                                     
 liability                       (1,039)     (4,470)       (878)      5,105 
                            ------------------------------------------------
Net income (loss) and                                                       
 comprehensive income (loss)                                                
 for the period               $     288   $   3,343   $  (1,235)  $  (6,621)
                            ------------------------------------------------
                            ------------------------------------------------

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
21st International Cloud Expo, taking place October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud strategy. Me...
SYS-CON Events announced today that DXWorldExpo has been named “Global Sponsor” of SYS-CON's 21st International Cloud Expo, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Digital Transformation is the key issue driving the global enterprise IT business. Digital Transformation is most prominent among Global 2000 enterprises and government institutions.
SYS-CON Events announced today that Datera, that offers a radically new data management architecture, has been named "Exhibitor" of SYS-CON's 21st International Cloud Expo ®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Datera is transforming the traditional datacenter model through modern cloud simplicity. The technology industry is at another major inflection point. The rise of mobile, the Internet of Things, data storage and Big...
Kubernetes is an open source system for automating deployment, scaling, and management of containerized applications. Kubernetes was originally built by Google, leveraging years of experience with managing container workloads, and is now a Cloud Native Compute Foundation (CNCF) project. Kubernetes has been widely adopted by the community, supported on all major public and private cloud providers, and is gaining rapid adoption in enterprises. However, Kubernetes may seem intimidating and complex ...
"Outscale was founded in 2010, is based in France, is a strategic partner to Dassault Systémes and has done quite a bit of work with divisions of Dassault," explained Jackie Funk, Digital Marketing exec at Outscale, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"We focus on SAP workloads because they are among the most powerful but somewhat challenging workloads out there to take into public cloud," explained Swen Conrad, CEO of Ocean9, Inc., in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"I think DevOps is now a rambunctious teenager – it’s starting to get a mind of its own, wanting to get its own things but it still needs some adult supervision," explained Thomas Hooker, VP of marketing at CollabNet, in this SYS-CON.tv interview at DevOps Summit at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"We are still a relatively small software house and we are focusing on certain industries like FinTech, med tech, energy and utilities. We help our customers with their digital transformation," noted Piotr Stawinski, Founder and CEO of EARP Integration, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"We've been engaging with a lot of customers including Panasonic, we've been involved with Cisco and now we're working with the U.S. government - the Department of Homeland Security," explained Peter Jung, Chief Product Officer at Pulzze Systems, in this SYS-CON.tv interview at @ThingsExpo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"We're here to tell the world about our cloud-scale infrastructure that we have at Juniper combined with the world-class security that we put into the cloud," explained Lisa Guess, VP of Systems Engineering at Juniper Networks, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"With Digital Experience Monitoring what used to be a simple visit to a web page has exploded into app on phones, data from social media feeds, competitive benchmarking - these are all components that are only available because of some type of digital asset," explained Leo Vasiliou, Director of Web Performance Engineering at Catchpoint Systems, in this SYS-CON.tv interview at DevOps Summit at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
Your homes and cars can be automated and self-serviced. Why can't your storage? From simply asking questions to analyze and troubleshoot your infrastructure, to provisioning storage with snapshots, recovery and replication, your wildest sci-fi dream has come true. In his session at @DevOpsSummit at 20th Cloud Expo, Dan Florea, Director of Product Management at Tintri, provided a ChatOps demo where you can talk to your storage and manage it from anywhere, through Slack and similar services with...
"Peak 10 is a hybrid infrastructure provider across the nation. We are in the thick of things when it comes to hybrid IT," explained Michael Fuhrman, Chief Technology Officer at Peak 10, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
As enterprise cloud becomes the norm, businesses and government programs must address compounded regulatory compliance related to data privacy and information protection. The most recent, Controlled Unclassified Information and the EU’s GDPR have board level implications and companies still struggle with demonstrating due diligence. Developers and DevOps leaders, as part of the pre-planning process and the associated supply chain, could benefit from updating their code libraries and design by in...
SYS-CON Events announced today that Calligo, an innovative cloud service provider offering mid-sized companies the highest levels of data privacy and security, has been named "Bronze Sponsor" of SYS-CON's 21st International Cloud Expo ®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Calligo offers unparalleled application performance guarantees, commercial flexibility and a personalised support service from its globally located cloud plat...